Obr Peer-spectives

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Sagar Lonial, MD, Professor and Chair, Hematology & Medical Oncology, Chief Medical Officer, Winship Cancer Institute of Emory University, discuss ALCYONE, GRIFFIN, and maintenance therapy (TOURMALINE-MM3), and other multiple myeloma clinical studies presented at the American Society of Hematology 2018 meeting

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson, discuss IMpassion130, SOLAR-1 and other breast cancer clinical studies presented at the meeting

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Barbara Burtness, MD, Professor of Medicine (Medical Oncology) at the Yale University School of Medicine, discuss Keynote-048 and other H&N clinical studies presented at the meeting

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss BRCA1+ ovarian patients, PARP inhibitors and the results of the SOLO-1 clinical trial

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute about targeted therapy, prevention, I-O in NSCLC, and I-O in SCLC

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Paul Bunn, MD, Distinguished Professor, Division of Medical Oncology, University of Colorado about prevention, I-O in NSCLC, and I-O in SCLC